Nanocarrier-Integrated Microneedles : Divulging the Potential of Novel Frontiers for Fostering the Management of Skin Ailments
The various kinds of nanocarriers (NCs) have been explored for the delivery of therapeutics designed for the management of skin manifestations. The NCs are considered as one of the promising approaches for the skin delivery of therapeutics attributable to sustained release and enhanced skin penetration. Despite the extensive applications of the NCs, the challenges in their delivery via skin barrier (majorly stratum corneum) have persisted. To overcome all the challenges associated with the delivery of NCs, the microneedle (MN) technology has emerged as a beacon of hope. Programmable drug release, being painless, and its minimally invasive nature make it an intriguing strategy to circumvent the multiple challenges associated with the various drug delivery systems. The integration of positive traits of NCs and MNs boosts therapeutic effectiveness by evading stratum corneum, facilitating the delivery of NCs through the skin and enhancing their targeted delivery. This review discusses the barrier function of skin, the importance of MNs, the types of MNs, and the superiority of NC-loaded MNs. We highlighted the applications of NC-integrated MNs for the management of various skin ailments, combinational drug delivery, active targeting, in vivo imaging, and as theranostics. The clinical trials, patent portfolio, and marketed products of drug/NC-integrated MNs are covered. Finally, regulatory hurdles toward benchtop-to-bedside translation, along with promising prospects needed to scale up NC-integrated MN technology, have been deliberated. The current review is anticipated to deliver thoughtful visions to researchers, clinicians, and formulation scientists for the successful development of the MN-technology-based product by carefully optimizing all the formulation variables.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Molecular pharmaceutics - (2024) vom: 25. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khairnar, Pooja [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Revised 25.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1021/acs.molpharmaceut.4c00144 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371495997 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371495997 | ||
| 003 | DE-627 | ||
| 005 | 20240426000724.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240426s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acs.molpharmaceut.4c00144 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1387.xml |
| 035 | |a (DE-627)NLM371495997 | ||
| 035 | |a (NLM)38660711 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khairnar, Pooja |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanocarrier-Integrated Microneedles |b Divulging the Potential of Novel Frontiers for Fostering the Management of Skin Ailments |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a The various kinds of nanocarriers (NCs) have been explored for the delivery of therapeutics designed for the management of skin manifestations. The NCs are considered as one of the promising approaches for the skin delivery of therapeutics attributable to sustained release and enhanced skin penetration. Despite the extensive applications of the NCs, the challenges in their delivery via skin barrier (majorly stratum corneum) have persisted. To overcome all the challenges associated with the delivery of NCs, the microneedle (MN) technology has emerged as a beacon of hope. Programmable drug release, being painless, and its minimally invasive nature make it an intriguing strategy to circumvent the multiple challenges associated with the various drug delivery systems. The integration of positive traits of NCs and MNs boosts therapeutic effectiveness by evading stratum corneum, facilitating the delivery of NCs through the skin and enhancing their targeted delivery. This review discusses the barrier function of skin, the importance of MNs, the types of MNs, and the superiority of NC-loaded MNs. We highlighted the applications of NC-integrated MNs for the management of various skin ailments, combinational drug delivery, active targeting, in vivo imaging, and as theranostics. The clinical trials, patent portfolio, and marketed products of drug/NC-integrated MNs are covered. Finally, regulatory hurdles toward benchtop-to-bedside translation, along with promising prospects needed to scale up NC-integrated MN technology, have been deliberated. The current review is anticipated to deliver thoughtful visions to researchers, clinicians, and formulation scientists for the successful development of the MN-technology-based product by carefully optimizing all the formulation variables | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a microneedles | |
| 650 | 4 | |a nanocarriers | |
| 650 | 4 | |a skin ailments | |
| 650 | 4 | |a synergistic effect | |
| 650 | 4 | |a theranostics | |
| 650 | 4 | |a transdermal delivery | |
| 700 | 1 | |a Phatale, Vivek |e verfasserin |4 aut | |
| 700 | 1 | |a Shukla, Shalini |e verfasserin |4 aut | |
| 700 | 1 | |a Tijani, Akeemat O |e verfasserin |4 aut | |
| 700 | 1 | |a Hedaoo, Aachal |e verfasserin |4 aut | |
| 700 | 1 | |a Strauss, Jordan |e verfasserin |4 aut | |
| 700 | 1 | |a Verana, Gabrielle |e verfasserin |4 aut | |
| 700 | 1 | |a Vambhurkar, Ganesh |e verfasserin |4 aut | |
| 700 | 1 | |a Puri, Ashana |e verfasserin |4 aut | |
| 700 | 1 | |a Srivastava, Saurabh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular pharmaceutics |d 2004 |g (2024) vom: 25. Apr. |w (DE-627)NLM154556807 |x 1543-8392 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:25 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.molpharmaceut.4c00144 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 25 |c 04 | ||